Grace Therapeutics, Inc.: Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application (NDA) Submission Expected in the First Half of 2025 PRI ...
Securing 5G edge network – what companies should know before stepping on the edge of tech
The byline explores 5G edge opportunities, security challenges, and safeguarding strategies for digital innovation.